Fresh Tracks Therapeutics, Inc. (DB: VCC)
Health Care · Biotechnology · US
€—
— today · — 1Y
Fresh Tracks Therapeutics, Inc. (DB: VCC) operates in the Biotechnology industry within the Health Care sector.
trading between 0.44 and 3.40.
Tweenvest scores Fresh Tracks Therapeutics, Inc. across four factors: quality 26/100, growth 0/100. Its strongest factor is quality.
VCC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $8.01M
- P/E
- —
- EPS
- -1.06
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- €3.40
- 52-week low
- €0.44
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 4
- Next earnings
- —
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
- ISIN
- US10802T2042
- Founded
- 2009
- Listed since
- Mar 10, 1993
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.